Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...
The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% <br / ...
This article explores the feasibility of simulated placements, incorporating digital technologies alongside classroom-based ...
Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.
Initiated the Phase 2 MoonStone trial, a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial, to evaluate the efficacy and safety of obexelimab in patients with Relapsing Multiple ...
CENDIFOX: Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers. The trial has completed ...
GlobalData on MSN6d
FDA grants breakthrough status to J&J’s nipocalimab for SjD treatmentThe US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
Solengepras is a potentially first-in-class, oral, non-dopaminergic investigational therapy in development for Parkinson’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback